{"id":3729,"date":"2025-04-22T16:58:45","date_gmt":"2025-04-22T13:58:45","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3729"},"modified":"2025-05-07T16:13:03","modified_gmt":"2025-05-07T13:13:03","slug":"satellos-sat-3247-phase-2-clinical-study-ready-to-launch","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-sat-3247-phase-2-clinical-study-ready-to-launch\/","title":{"rendered":"Satellos, Duchenne Musk\u00fcler Distrofi Tedavisi \u0130\u00e7in SAT-3247&#039;nin 2. Faz Klinik \u00c7al\u0131\u015fmas\u0131n\u0131 Ba\u015flatmaya Haz\u0131rlan\u0131yor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Kas hastal\u0131klar\u0131 i\u00e7in rejeneratif tedaviler geli\u015ftirmeye odaklanan klinik a\u015famadaki bir biyoteknoloji \u015firketi olan Satellos Bioscience, ClinicalTrials.Gov&#039;da Duchenne Musk\u00fcler Distrofi&#039;yi (DMD) hedef alan \u00f6nc\u00fc ila\u00e7 aday\u0131 SAT-3247&#039;nin 2. Faz klinik \u00e7al\u0131\u015fmas\u0131n\u0131 ba\u015flatmaya haz\u0131rland\u0131\u011f\u0131n\u0131 duyurdu. Bu, \u015firketin bu nadir ve zay\u0131flat\u0131c\u0131 genetik bozukluktan etkilenen bireylere d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir tedavi sunma misyonunda \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131n\u0131 i\u015faret ediyor.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Satellos SAT-3247 Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131<\/h2><nav><ul><li class=\"\"><a href=\"#what-is-sat-3247\">SAT-3247 nedir?<\/a><\/li><li class=\"\"><a href=\"#why-this-matters-for-duchenne-muscular-dystrophy\">Duchenne Musk\u00fcler Distrofisi \u0130\u00e7in Bunun \u00d6nemi Nedir?<\/a><\/li><li class=\"\"><a href=\"#whats-next-for-the-clinical-trial\">Klinik Ara\u015ft\u0131rman\u0131n S\u0131rada Ne Var?<\/a><\/li><li class=\"\"><a href=\"#a-new-chapter-in-muscle-regeneration\">Kas Yenilenmesinde Yeni Bir B\u00f6l\u00fcm<\/a><\/li><li class=\"\"><a href=\"#how-can-my-son-participate-in-the-clinical-trial\">O\u011flum SAT-3247 Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131na Nas\u0131l Kat\u0131labilir?<\/a><\/li><li class=\"\"><a href=\"#about-satellos-bioscience\">Satellos Bioscience Hakk\u0131nda<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sat-3247\">SAT-3247 nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247, kas k\u00f6k h\u00fccre polaritesini hedef alarak v\u00fccudun kas yenileme yetene\u011fini geri kazand\u0131rmak i\u00e7in tasarlanm\u0131\u015f, s\u0131n\u0131f\u0131nda ilk olan k\u00fc\u00e7\u00fck molek\u00fcl terapisidir. Esas olarak kas dejenerasyonunu yava\u015flatmay\u0131 ama\u00e7layan mevcut DMD terapilerinin aksine, SAT-3247, hasarl\u0131 kas dokusunu yeniden in\u015fa etmek ve onarmak i\u00e7in v\u00fccudun do\u011fal yenileyici yollar\u0131n\u0131 aktive etmeye odaklan\u0131r ve hastal\u0131k modifikasyonuna potansiyel olarak \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir yakla\u015f\u0131m sunar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/satellos-sat-3247-stem-cell-approach-may-restore-muscle-regeneration-in-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Satellos SAT-3247 K\u00f6k H\u00fccre Yakla\u015f\u0131m\u0131 Duchenne Musk\u00fcler Distrofi&#039;de Kas Yenilenmesini Geri Kazand\u0131rabilir<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-this-matters-for-duchenne-muscular-dystrophy\">Duchenne Musk\u00fcler Distrofisi \u0130\u00e7in Bunun \u00d6nemi Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne Musk\u00fcler Distrofi, \u00f6ncelikle erkek \u00e7ocuklar\u0131n\u0131 etkileyen, kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fcne, hareket kabiliyetinin kayb\u0131na ve erken \u00f6l\u00fcme neden olan ilerleyici bir genetik rahats\u0131zl\u0131kt\u0131r. Mevcut tedaviler s\u0131n\u0131rl\u0131d\u0131r ve \u00e7o\u011fu hastal\u0131\u011f\u0131n seyrini durdurmak veya tersine \u00e7evirmek yerine semptom y\u00f6netimine odaklan\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247 i\u00e7in Faz 2 klinik denemelerinin ba\u015flat\u0131lmas\u0131, bu kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiyaca y\u00f6nelik kritik bir ad\u0131md\u0131r. Satellos&#039;ye g\u00f6re ama\u00e7, umut verici Faz 1 sonu\u00e7lar\u0131n\u0131n ard\u0131ndan ilac\u0131n g\u00fcvenli\u011fini, tolere edilebilirli\u011fini ve etkinli\u011fini daha geni\u015f bir DMD hasta grubunda de\u011ferlendirmektir.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"646\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1024x646.jpg\" alt=\"Satellos SAT-3247 Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131\" class=\"wp-image-3735\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1024x646.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-300x189.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-768x485.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-18x12.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-666x420.jpg 666w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-150x95.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-696x439.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials.jpg 1057w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"whats-next-for-the-clinical-trial\">Klinik Ara\u015ft\u0131rman\u0131n S\u0131rada Ne Var?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos, deneme sahas\u0131 aktivasyonu ve hasta al\u0131m\u0131 i\u00e7in haz\u0131rl\u0131klar\u0131 tamamlad\u0131\u011f\u0131n\u0131 belirtti. Faz 2 denemesi Avustralya&#039;daki St. Vincent Hastanesi&#039;nde ger\u00e7ekle\u015ftirilecek ve do\u011frulanm\u0131\u015f DMD tan\u0131s\u0131 olan 18 ila 40 ya\u015f aras\u0131 erkekleri kapsayacak. \u00c7al\u0131\u015fma ayr\u0131ca kas rejenerasyonu ve i\u015flevsel iyile\u015ftirmelerin biyobelirte\u00e7lerini de\u011ferlendirecek ve Duchenne i\u00e7in tedavi alan\u0131nda potansiyel olarak yeni bir \u00f6l\u00e7\u00fct belirleyecek.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos CEO&#039;su Dr. Frank Gleeson, &quot;SAT-3247&#039;yi Faz 2&#039;ye ta\u015f\u0131maktan heyecan duyuyoruz. Bu ad\u0131m, Duchenne i\u00e7in rejeneratif t\u0131p yakla\u015f\u0131m\u0131na \u00f6nc\u00fcl\u00fck etme ve bu y\u0131k\u0131c\u0131 hastal\u0131ktan etkilenen hastalar\u0131n ve ailelerinin hayatlar\u0131n\u0131 iyile\u015ftirme taahh\u00fcd\u00fcm\u00fcz\u00fc yans\u0131t\u0131yor.&quot; dedi.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"575\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-1024x575.jpg\" alt=\"Satellos SAT-3247 Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131\" class=\"wp-image-3736\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-1024x575.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-300x168.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-768x431.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-18x10.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-748x420.jpg 748w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-150x84.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-696x391.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1.jpg 1060w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06867107\" target=\"_blank\" rel=\"noreferrer noopener\">Satellos SAT-3247 Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131: NCT06867107<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"a-new-chapter-in-muscle-regeneration\">Kas Yenilenmesinde Yeni Bir B\u00f6l\u00fcm<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247 ile Satellos, yaln\u0131zca bilimsel yenili\u011fin s\u0131n\u0131rlar\u0131n\u0131 zorlamakla kalm\u0131yor, ayn\u0131 zamanda d\u00fcnya \u00e7ap\u0131nda binlerce aileye umut da sa\u011fl\u0131yor. Ba\u015far\u0131l\u0131 olursa, bu terapi kas distrofileri ve ilgili durumlar i\u00e7in yeni bir rejeneratif tedavi s\u0131n\u0131f\u0131n\u0131n \u00f6nc\u00fcs\u00fc olabilir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-can-my-son-participate-in-the-clinical-trial\">O\u011flum SAT-3247 Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131na Nas\u0131l Kat\u0131labilir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos, SAT-3247 Faz 2 klinik \u00e7al\u0131\u015fmalar\u0131n\u0131n Avustralya&#039;da y\u00fcr\u00fct\u00fclece\u011fini duyurmu\u015f olsa da, Avustralya&#039;ya seyahat etme imk\u00e2n\u0131 olan ve kriterleri kar\u015f\u0131layan DMD hastalar\u0131n\u0131n a\u015fa\u011f\u0131daki ileti\u015fim bilgilerini kullanarak Satellos ile ileti\u015fime ge\u00e7melerini \u00f6neriyoruz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u0130sim<\/strong>: Satellos T\u0131bbi \u0130\u015fler\/Klinik Geli\u015ftirme<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Telefon Numaras\u0131<\/strong>: +61 3 8736 1750<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-posta<\/strong>: medicalinfo@satellos.com<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"685\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-1024x685.jpg\" alt=\"O\u011flum SAT-3247 Faz 2 Klinik \u00c7al\u0131\u015fmas\u0131na Nas\u0131l Kat\u0131labilir?\" class=\"wp-image-3827\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-1024x685.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-300x201.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-768x514.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-18x12.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-628x420.jpg 628w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-150x100.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-696x466.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info.jpg 1061w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"about-satellos-bioscience\">Satellos Bioscience Hakk\u0131nda<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos Bioscience, kas dejenerasyonunu i\u00e7eren hastal\u0131klar i\u00e7in yeni rejeneratif ila\u00e7lar ke\u015ffetmeye ve geli\u015ftirmeye odaklanan Toronto merkezli bir biyoteknoloji \u015firketidir. Tescilli MyoReGenX\u2122 platformundan yararlanan Satellos, kas distrofilerinin ilerlemesini tersine \u00e7evirmek i\u00e7in kas k\u00f6k h\u00fccre biyolojisinin kilidini a\u00e7may\u0131 ama\u00e7lamaktad\u0131r.<\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience, a clinical-stage biotechnology company focused on developing regenerative therapies for muscle diseases, has announced at ClinicalTrials.Gov it is preparing to initiate a Phase 2 clinical study of its lead drug candidate, SAT-3247, targeting Duchenne Muscular Dystrophy (DMD). This marks a significant milestone in the company\u2019s mission to offer a transformative treatment for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3739,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,254,251,252,253],"class_list":["post-3729","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-frank-gleeson","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3729"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3739"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}